Sodium,calcium,mag,pot Oxybate
Brand name: Xywav
Rank #251 of 500 drugs by total cost
$51.1M
Total Cost
3,234
Total Claims
$51.1M
Total Cost
181
Prescribers
$16K
Cost per Claim
17
Beneficiaries
3,234
30-Day Fills
$282K
Avg Cost/Provider
18
Avg Claims/Provider
About Sodium,calcium,mag,pot Oxybate
Sodium,calcium,mag,pot Oxybate (sold as Xywav) was prescribed 3,234 times by 181 Medicare Part D providers in 2023, costing the program $51.1M. At $16K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 248 | Epoetin Alfa (Epogen) | $51.4M | 34,952 |
| 249 | Nifedipine (Nifedipine Er) | $51.2M | 1,249,866 |
| 250 | Clobetasol Propionate (Clobetasol Propionate) | $51.2M | 758,575 |
| 251 | Sodium,calcium,mag,pot Oxybate (Xywav) | $51.1M | 3,234 |
| 252 | Eslicarbazepine Acetate (Aptiom) | $51.1M | 31,472 |
| 253 | Risdiplam (Evrysdi) | $51.1M | 1,891 |
| 254 | Amikacin Liposomal/Neb.Accessr (Arikayce) | $50.5M | 3,394 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology